Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > REGULATORY
REGULATORY
- Xarelto Survey Scandal “Very Regrettable”: Shiozaki
April 12, 2017
- CEFP Social Security Working Group Raises Questions on Price Maintenance Premium, Biosimilar Policy
April 12, 2017
- MHLW to Continue Withholding HPV Vaccine Recommendation
April 11, 2017
- 41 New APIs Approved in FY2016 in Japan: PMDA
April 11, 2017
- MHLW Advisory Panel to Review Mundipharma’s Injectable Pralatrexate on April 21
April 11, 2017
- Certified IRBs to Review How Monitoring/Audits Will Be Conducted for “Specified Clinical Research”: Official
April 10, 2017
- MHLW to Mull Use of Data from “Specified Clinical Research” for Drug Review: Official
April 10, 2017
- Clinical Research Bill Passed into Law
April 7, 2017
- Ex-Min. Tamura’s Study Group Boots Up with Backing of 17 Healthcare-Related Organizations
April 7, 2017
- Domestic Drug Production Logs 1st Rise in 4 Years: 2015 MHLW Survey
April 6, 2017
- Rare Symposium Planned after Closed-Door Regulatory Head Confab in October
April 6, 2017
- AMED Inks Collaboration Pact with Spanish Authority
April 6, 2017
- “I Don’t Use Biosimilars,” Says Ex-Chief of Japan College of Rheumatology
April 5, 2017
- MHLW Releases “Blue Book” Generic Data List
April 4, 2017
- MHLW Sets Up Office for Startup Support, Starts Receiving Applications for Consultations
April 4, 2017
- MHLW Issues Optimal Use Guidelines for Repatha, Praluent
April 3, 2017
- MHLW to Launch Conditional Early Approval for Medical Devices Too
April 3, 2017
- Cabinet Presents Reform of Drug Discovery Support Network Including Use of CROs, Transfer of Drug Makers’ Employees
April 3, 2017
- Avigan Might Be Used for Pandemic Influenza if Existing NA Inhibitors Are Ineffective: Expert Council
April 3, 2017
- CEFP Kicks Off Discussions on Economic and Fiscal Policy Blueprint for 2017
March 31, 2017
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…